Study: SPECT biomarker assessment could aid ovarian cancer treatment

09/18/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using SPECT to assess expression of vascular cell adhesion molecule-1 may help predict therapeutic response and possibly improve outcomes for patients with metastatic ovarian cancer. Among 32 patients assessed with SPECT imaging, researchers found that VCAM-1 expression was present in 15% of women after chemotherapy, compared with 72% of those who only received surgery. "[T]hese observations indicate that in addition to the presence of VCAM-1 at the earliest stages of peritoneal spread (i.e., stage II patients with secondary implants), expression is responsive to treatment," researchers wrote.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX